The medical management of inflammatory bowel disease (IBD) is evolving toward a personalized medicine-based model.
Dr Brian Feagan and colleagues from Canada examine the current application of personalized medicine to the management of IBD.
|Defined targets that guide intensification of therapy are critical interventions|
|American Journal of Gastroenterology|
The team noted that modern therapeutic algorithms that feature use of tumor necrosis factor (TNF) antagonists in combination with immunosuppressive are highly effective when initiated in high-risk patients early in the course of disease.
Defined targets that guide intensification of therapy are critical interventions.
Dr Feagan's team concludes, "In this model, therapy is optimized through appropriate pretreatment testing, therapeutic drug monitoring, and patient-based monitoring strategies."